Eli Lilly and Company (LLY) Q3 2025 Financial Results Summary

Released on October 30, 2025, Eli Lilly and Company announced its financial results for the third quarter of 2025, showcasing significant growth across multiple areas.

Key Financial Highlights

• Revenue:
• Increased 54% to $17.60 billion compared to $11.44 billion in Q3 2024.
• Driven by a 62% increase in volume, although 10% was offset by lower realized prices.

• Key Products revenue surged to $11.98 billion, primarily fueled by Mounjaro and Zepbound.

• Net Income:

• Reported net income was $5.58 billion, a notable increase compared to $970.3 million in Q3 2024.

• Earnings per share (EPS) rose to $6.21 on a reported basis (up from $1.07) and $7.02 on a non-GAAP basis (up from $1.18).

• Gross Margin:

• Increased 57% to $14.59 billion, with gross margin as a percentage of revenue at 82.9%, up 1.9 percentage points compared to Q3 2024.

• Research and Development (R&D):

• Expenses rose 27% to $3.47 billion, accounting for 19.7% of revenue, reflecting continued investment in both early and late-stage projects.

• Marketing, Selling, and Administrative Expenses:

• Increased 31% to $2.74 billion, driven by promotional efforts linked to product launches.

• Acquired In-Process R&D Charges:

• Reported as $655.7 million, a 77% decrease from $2.83 billion in Q3 2024.

• Asset Impairment, Restructuring, and Special Charges:

• Reported at $364.9 million, compared to $81.6 million in Q3 2024.

• Effective Tax Rate:

• The effective tax rate for Q3 2025 was 22.8%, down from 38.9% in Q3 2024.

Regional Performance

• U.S. Revenue:

• Increased 45% to $11.30 billion, due to a 60% rise in volume, despite a 15% decrease from lower realized prices.

• International Revenue:

• Rose 74% to $6.30 billion, boosted by a 66% growth in volume and a favorable 6% impact from foreign exchange rates.

Noteworthy Products

• Mounjaro:

• Q3 revenue increased 109% to $6.52 billion.

• Zepbound:

• U.S. revenue soared 184% to $3.57 billion.

• Verzenio:

• Worldwide revenue grew 7% to $1.47 billion.

Shareholder Returns

• Dividends:
• Declared a quarterly dividend of $1.50 per share, up 15% from $1.30 in Q3 2024.

Future Guidance

• Revenue Guidance for 2025:

• Increased to a range of $63.0 billion to $63.5 billion.

• EPS Guidance for 2025:

• Reported EPS expected between $21.80 and $22.50 and non-GAAP EPS between $23.00 and $23.70.

Manufacturing and Regulatory Developments

• Announced two new manufacturing facilities in Virginia and Texas and an expansion in Puerto Rico to enhance production capacity.

• Regulatory achievements included:

• U.S. FDA approval of Inluriyo (imlunestrant) for advanced breast cancer.
• Progress in the pipeline with successful Phase 3 trials of orforglipron for diabetes and obesity treatment, leading to upcoming global submissions.

Eli Lilly’s Q3 2025 results reflect a robust financial position and ongoing commitment to innovation in biopharmaceuticals, underpinning its optimistic outlook supported by strategic investments and product performance.

Here are the extracted tables from the press release:

Income Statement – CONDENSED CONSOLIDATED STATEMENTS OF INCOME

Balance Sheet – CONDENSED CONSOLIDATED BALANCE SHEETS